rpl-28 Antibody

What is RPL28 and what is its role in cellular function?

RPL28 (Ribosomal Protein L28) is a component of the large 60S ribosomal subunit that plays an essential role in the ribosome, the organelle responsible for protein synthesis in the cell . It belongs to the L28E family of ribosomal proteins and is located primarily in the cytoplasm . As a structural component of ribosomes, RPL28 coordinates with other ribosomal proteins including RPL5 and RPL11, which are also involved in the assembly of the large ribosomal subunit . Together, these proteins ensure effective translation and synthesis of proteins required by the cell. RPL28 has a calculated molecular weight of approximately 15.7 kDa . Beyond its primary role in translation, research has revealed that RPL28 plays a significant role in regulating MHC class I peptide generation for immunosurveillance, highlighting its multifunctional nature in cellular processes .

What species reactivity can researchers expect from commercial RPL28 antibodies?

Commercial RPL28 antibodies demonstrate varied species reactivity profiles that researchers should consider when selecting reagents for their experiments. Several antibodies show cross-reactivity with human, mouse, and rat samples . For instance, the Boster Bio Anti-RPL28 Antibody (catalog # A10323-1) has confirmed reactivity to RPL28 in human, mouse, and rat specimens . This multi-species reactivity is particularly valuable for comparative studies across different model organisms. The broad reactivity profile can be attributed to the high evolutionary conservation of ribosomal proteins across mammalian species. When planning experiments, researchers should review the validation data provided by manufacturers, which typically includes Western blot, immunohistochemistry, or immunocytochemistry results demonstrating species-specific reactivity . It's also advisable to validate new antibodies in your specific experimental system, even when the manufacturer claims reactivity for your species of interest.

What are the primary applications for RPL28 antibodies in research?

RPL28 antibodies serve multiple experimental applications in molecular and cellular biology research. The primary validated applications include Western Blot (WB), Immunohistochemistry (IHC), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunocytochemistry/Immunofluorescence (ICC/IF) . For Western blotting, manufacturers typically recommend dilution ranges between 1:500-1:2000, with optimization required for specific experimental conditions . In IHC applications, RPL28 antibodies have been successfully used at dilutions of 1:100-1:300 to visualize expression patterns in formalin-fixed paraffin-embedded (FFPE) tissue sections, including human ovarian cancer and pancreatic tissues . For ELISA applications, significantly higher dilutions (e.g., 1:20000) are typically recommended . Recent publications have employed RPL28 antibodies in cellular localization studies, ribosome assembly research, and investigations into translation regulation mechanisms. Importantly, researchers have also utilized these antibodies in cancer research to study variable expression of RPL28 in colorectal cancers compared to adjacent normal tissues .

How does RPL28 impact MHC class I peptide generation and immunosurveillance?

Research has revealed a nuanced role for RPL28 in regulating the MHC class I antigen presentation system, which is critical for T cell immunosurveillance of cancers and viruses. Unlike most ribosomal proteins that simply facilitate protein synthesis, RPL28 appears to have an additional regulatory function in immune pathways. Through knockdown experiments, researchers have demonstrated that depleting RPL28 significantly increases the generation of MHC class I peptides, specifically enhancing Kb-SIINFEKL presentation regardless of the source protein . This effect occurs without altering source protein expression or significantly changing β2m cell surface expression or total cell-associated Kb levels.

The mechanism appears to involve modulating the supply of peptides available for loading onto MHC class I molecules in the endoplasmic reticulum. Interestingly, this role of RPL28 contrasts with that of RPL6, which decreases ubiquitin-dependent peptide presentation when depleted . This opposing regulatory effect suggests a complex interplay between specific ribosomal proteins in controlling antigen presentation. Furthermore, RiboMethSeq analysis has shown that RPL28 depletion alters the methylation status of specific 28S rRNA sites (Am2388, Gm4588, and Gm4607), suggesting that RPL28 may influence immune function through epigenetic mechanisms regulating ribosome activity . These findings indicate that RPL28 serves as a negative regulator of MHC class I peptide generation, with potential implications for enhancing immunotherapy approaches in cancer and infectious disease contexts.

What is the significance of RPL28 in cancer research?

RPL28 has emerged as a protein of interest in cancer biology, with variable expression patterns observed in different malignancies. Research has documented differential expression of RPL28 in colorectal cancers compared to adjacent normal tissues, although direct correlations between expression levels and disease severity have not been definitively established . The significance of RPL28 in cancer extends beyond its canonical role in ribosome function and protein synthesis.

Recent immunohistochemical analyses using RPL28-specific antibodies have demonstrated distinct staining patterns in human ovarian cancer tissues, suggesting potential diagnostic or prognostic applications . The protein's involvement in MHC class I peptide generation further connects it to cancer immunosurveillance mechanisms, as altered RPL28 expression or function could potentially influence how cancer cells present antigens to the immune system .

From a mechanistic perspective, RPL28 may contribute to cancer progression through its interactions with other ribosomal proteins including RPL5 and RPL11, which have recognized tumor-suppressive functions through p53 activation. Dysregulation of these coordinated activities could potentially contribute to carcinogenesis through altered translational control . Additionally, the role of RPL28 in ribosome assembly suggests that its abnormal expression could contribute to the altered protein synthesis patterns characteristic of many cancer cells. While research into RPL28's specific contributions to cancer biology remains ongoing, these findings suggest it may represent both a biomarker and potential therapeutic target in oncology research.

What alterations in ribosome function occur with RPL28 knockdown?

RPL28 knockdown induces significant structural and functional changes in ribosomes that extend beyond simple depletion of a structural component. Research has revealed that reducing RPL28 expression modifies ribosomes through multiple mechanisms, with potential implications for translation regulation and cellular homeostasis.

One notable effect is the alteration of rRNA methylation patterns. RiboMethSeq analysis demonstrated that RPL28 depletion specifically modulates the methylation status of three distinct 28S rRNA sites: Am2388, Gm4588, and Gm4607 . These methylation changes likely influence ribosome structure and function, as rRNA modifications are known to affect translation fidelity and efficiency. Additionally, RPL28 knockdown appears to modulate ribosome-associated proteins without necessarily altering other ribosomal proteins, suggesting a specific regulatory role rather than general destabilization of ribosomal structure .

What are the optimal conditions for using RPL28 antibodies in Western Blot experiments?

For successful Western blot detection of RPL28, researchers should implement specific optimization strategies tailored to this relatively small (15.7 kDa) ribosomal protein. Based on manufacturer recommendations and published protocols, the following conditions represent a starting point for optimal results:

When troubleshooting, researchers should be aware that RPL28 antibody specificity can be validated using siRNA knockdown as a negative control, as demonstrated in validation experiments showing significant signal reduction in U2OS cells transfected with RPL28-targeting siRNA probes . Additionally, careful optimization of extraction methods is crucial since ribosomal proteins are abundant but can be lost during certain extraction procedures. For specialized applications examining ribosome-associated versus free RPL28, sucrose gradient fractionation prior to Western blotting may provide valuable insights into the protein's distribution within different cellular compartments.

What are the recommended procedures for RPL28 antibody validation?

Comprehensive validation of RPL28 antibodies is essential for ensuring experimental reliability and reproducibility. Based on established protocols and manufacturer recommendations, researchers should implement a multi-faceted validation approach:

• Knockdown/Knockout Controls: Validate specificity through RPL28 knockdown using siRNA or CRISPR-Cas9 technologies. Western blot analysis comparing control and RPL28-depleted samples should demonstrate significant reduction in signal intensity. For example, validation studies with anti-RPL28 antibody ab254927 successfully demonstrated reduced signal in U2OS cells transfected with two different siRNA probes targeting RPL28 .

• Multi-application Validation: Confirm antibody performance across multiple experimental platforms including Western blot, immunohistochemistry, and immunofluorescence to establish consistent detection patterns. Complete validation should include:

  • Western blot: Verification of a single band at the expected molecular weight (approximately 15.7 kDa)

  • IHC: Assessment of staining patterns in known RPL28-expressing tissues with appropriate controls

  • ICC/IF: Evaluation of subcellular localization consistent with ribosomal distribution

• Positive Control Selection: Include lysates from cell lines known to express RPL28 at detectable levels, such as HepG2, MCF7, or U2OS cells, which have been successfully used in validation studies .

• Cross-reactivity Assessment: For antibodies claimed to detect RPL28 across multiple species, validate using samples from each target species to confirm cross-reactivity.

• Peptide Competition Assays: When available, use blocking peptides corresponding to the immunogen sequence to confirm binding specificity through signal abolishment.

• Orthogonal Method Comparison: Compare antibody-based detection with orthogonal methods such as mass spectrometry or RNA expression analysis to corroborate protein identification and expression levels.

Implementing this comprehensive validation strategy ensures that experimental findings genuinely reflect RPL28 biology rather than potential artifacts from non-specific antibody binding.

What are the optimal fixation and permeabilization methods for detecting RPL28 in immunofluorescence studies?

Successful detection of RPL28 in immunofluorescence studies requires careful optimization of fixation and permeabilization conditions to preserve protein epitopes while enabling antibody access to this primarily cytoplasmic ribosomal protein. Based on published protocols and manufacturer recommendations, the following methodology has demonstrated effectiveness:

Recommended Protocol:

• Fixation: Paraformaldehyde (PFA) fixation at 4% concentration for 15-20 minutes at room temperature has proven effective for RPL28 detection, preserving cellular architecture while maintaining epitope accessibility . This approach was successfully employed in MCF7 cells immunostained with anti-RPL28 antibody ab254927.

• Permeabilization: Triton X-100 at 0.1-0.25% concentration for 10 minutes provides appropriate permeabilization to facilitate antibody penetration while preserving subcellular structures . Alternative permeabilization agents such as 0.5% saponin may be considered for applications requiring milder permeabilization conditions.

• Blocking: 1-5% BSA or normal serum (matching the species of the secondary antibody) in PBS for 30-60 minutes effectively reduces background staining.

• Antibody Concentration: For primary incubation, concentrations of 2-4 μg/ml have been validated for specific RPL28 detection, though optimization may be necessary depending on the specific antibody and cell type .

• Counterstaining: DAPI nuclear counterstaining facilitates visualization of RPL28's primarily cytoplasmic localization, allowing clear differentiation from nuclear components.

When implementing this protocol, researchers should be aware that RPL28 predominantly localizes to the cytoplasm with potential enrichment in areas of active translation. Expected staining patterns include diffuse cytoplasmic signal with potential enrichment in the perinuclear region corresponding to rough endoplasmic reticulum. Validation experiments should include appropriate controls, including secondary-only controls and ideally RPL28-depleted cells, to confirm staining specificity.

How should researchers address high background issues when using RPL28 antibodies?

High background signal presents a common challenge when working with antibodies against abundant ribosomal proteins like RPL28. Researchers can implement several strategies to improve signal-to-noise ratio and obtain cleaner results:

• Optimized Blocking Conditions: Extend blocking time to 2 hours or overnight using 5% BSA or 5% milk in PBS-T/TBS-T. For particularly problematic samples, consider dual blocking with a combination of normal serum (2-5%) from the secondary antibody host species plus BSA.

• Antibody Dilution Optimization: Conduct a systematic dilution series to identify the optimal antibody concentration that maintains specific signal while reducing background. For Western blotting, starting ranges between 1:500-1:2000 are recommended, while IHC applications typically require more concentrated solutions (1:100-1:300) .

• Reduced Antibody Incubation Temperature: Conduct primary antibody incubation at 4°C overnight rather than at room temperature to enhance specific binding while reducing non-specific interactions.

• Modified Wash Protocols: Implement extended and additional washing steps after both primary and secondary antibody incubations. Increasing wash buffer stringency by adjusting salt concentration or adding 0.1% Tween-20 can help eliminate weakly bound antibodies.

• Secondary Antibody Cross-Adsorption: Use cross-adsorbed secondary antibodies specifically designed to minimize species cross-reactivity, particularly important when working with tissue samples.

• Sample-Specific Considerations: For IHC applications, implement tissue-specific antigen retrieval optimization and consider additional blocking steps with avidin/biotin if using biotinylated detection systems. For Western blots, fresh preparation of samples and inclusion of additional protease inhibitors may reduce degradation products that contribute to background.

• Validation Controls: Include isotype controls matched to the primary antibody's host species and concentration, as well as secondary-only controls to distinguish between primary and secondary antibody-related background.

By systematically implementing these approaches while maintaining appropriate positive and negative controls, researchers can significantly improve the specificity of RPL28 detection across different experimental platforms.

How can researchers distinguish between specific and non-specific findings when studying RPL28?

Distinguishing specific from non-specific findings when studying RPL28 requires implementing multiple validation strategies tailored to this ubiquitously expressed ribosomal protein. Researchers should employ the following approaches to ensure experimental robustness:

• Genetic Validation: The gold standard for confirming antibody specificity is demonstrating signal reduction following target depletion. Implement siRNA knockdown of RPL28 as demonstrated in validation studies with antibody ab254927, where U2OS cells transfected with two different siRNA probes showed significantly reduced RPL28 signal by Western blot . For definitive validation, CRISPR-Cas9 knockout can provide complete elimination of the target protein.

• Multiple Antibody Approach: Utilize at least two different antibodies targeting distinct epitopes of RPL28. Concordant results between antibodies raised against different regions of the protein strongly support specific detection. For instance, comparing results between antibodies targeting the full-length protein (ab193164) versus the C-terminal region (ab254927) can validate findings .

• Predicted Molecular Weight Confirmation: RPL28 has a calculated molecular weight of approximately 15.7 kDa . In Western blot applications, specific detection should yield a predominant band at this position, while additional bands may indicate non-specific binding or post-translational modifications.

• Expected Subcellular Localization: RPL28 should demonstrate primarily cytoplasmic localization with potential enrichment in the perinuclear region corresponding to rough endoplasmic reticulum. Immunofluorescence patterns significantly deviating from this distribution warrant further validation.

• Peptide Competition Assays: When available, pre-incubation of the antibody with its immunizing peptide should abolish specific signals while non-specific binding may persist. Some manufacturers offer blocking peptides specifically designed for their RPL28 antibodies .

• Cross-species Consensus: For evolutionarily conserved proteins like RPL28, detection patterns should show consistency across validated species. Significant discrepancies between human, mouse, and rat samples may indicate non-specific binding when using antibodies validated for cross-reactivity .

• Correlation with mRNA Expression: Integrate protein-level findings with transcriptomic data when possible, as correlation between RPL28 protein detection and mRNA expression provides additional validation of specificity.

By implementing these comprehensive validation strategies, researchers can confidently distinguish between specific and non-specific findings in RPL28 studies, ensuring experimental reliability and reproducibility.

What approaches can resolve contradictory results when using different RPL28 antibodies?

When facing contradictory results with different RPL28 antibodies, researchers should implement a systematic troubleshooting approach to identify the sources of discrepancy and determine which findings most accurately reflect the biological reality. The following strategies offer a methodical path to resolving such contradictions:

• Epitope Mapping Analysis: Review the documentation for each antibody to determine their target epitopes within the RPL28 protein. Antibodies targeting different domains may yield varying results if:

  • Post-translational modifications mask specific epitopes

  • Protein-protein interactions within the ribosome complex affect epitope accessibility

  • Alternative splicing variants of RPL28 are differentially recognized

• Validation Status Assessment: Critically evaluate the validation data for each antibody, including:

  • Knockdown/knockout controls demonstrating specificity

  • Publications citing the antibody in similar applications

  • Manufacturer validation across multiple applications

  For instance, antibodies validated through siRNA knockdown showing clear signal reduction provide stronger evidence of specificity .

• Application-Specific Optimization: Some antibodies perform optimally in specific applications but poorly in others. Test each antibody across multiple dilutions and conditions specifically optimized for:

  • Western blotting (different transfer methods, blocking agents)

  • Immunohistochemistry (varied antigen retrieval methods)

  • Immunofluorescence (alternative fixation protocols)

• Independent Validation Methods: Implement orthogonal approaches to validate findings, such as:

  • Mass spectrometry identification of RPL28

  • RNA interference combined with phenotypic assays

  • Fluorescent protein tagging to track RPL28 localization

• Cross-Laboratory Validation: If resources permit, have contradictory findings independently replicated in different laboratories to eliminate environment-specific variables.

• Monoclonal vs. Polyclonal Consideration: Recognize the inherent differences between these antibody types. Polyclonal antibodies may detect multiple epitopes and potentially show cross-reactivity but offer robust detection, while monoclonals provide high specificity for a single epitope but may be sensitive to epitope modification or masking.

• Integrated Data Analysis: When contradictions persist, implement a weight-of-evidence approach that prioritizes findings supported by:

  • Multiple antibodies showing concordant results

  • Orthogonal validation methods

  • Consistency with established literature

By systematically implementing these approaches, researchers can resolve contradictory results and establish which antibodies provide the most reliable representation of RPL28 biology in their specific experimental context.

What is the significance of RPL28 expression variation in cancer and disease contexts?

Emerging research suggests that RPL28 expression variations may have significant implications in cancer biology and other pathological conditions. Variable expression of RPL28 has been documented in colorectal cancers compared to adjacent normal tissues, although direct correlations between expression levels and disease severity remain to be fully established . This variability suggests potential roles for RPL28 beyond its canonical function in ribosome assembly and protein synthesis.

The significance of RPL28 in disease contexts may be partially explained by its involvement in MHC class I peptide generation for immunosurveillance . As demonstrated through knockdown experiments, RPL28 appears to negatively regulate peptide presentation, with its depletion enhancing MHC class I peptide display. This function implies that altered RPL28 expression could impact cancer immunosurveillance mechanisms, potentially affecting how tumors are recognized by the immune system.

Furthermore, ribosomal proteins including RPL28 coordinate with tumor suppressors like RPL5 and RPL11 . These interactions suggest that dysregulation of RPL28 could potentially impact tumor-suppressive pathways. Research has shown that certain ribosomal proteins contribute to p53 activation under ribosomal stress, forming part of the nucleolar stress response that maintains cellular homeostasis.

From a methodological perspective, researchers investigating RPL28 in disease contexts should implement comprehensive approaches including:

• Quantitative assessment of expression levels across multiple patient samples

• Correlation with clinical outcomes and pathological features

• Functional studies to determine the consequences of RPL28 modulation

• Integration with genomic data to identify potential mutations or alterations

These investigations may ultimately reveal whether RPL28 represents a potential biomarker or therapeutic target in specific disease contexts, particularly in cancers where ribosome biogenesis and function are frequently dysregulated.

What role does RPL28 play in ribosomal RNA methylation and epigenetic regulation?

Recent research has revealed that RPL28 has unexpected functions in modulating ribosomal RNA (rRNA) methylation patterns, suggesting a previously unrecognized role in epigenetic regulation of translation. RiboMethSeq analysis has demonstrated that RPL28 depletion specifically alters the methylation status of three distinct sites within 28S rRNA: Am2388, Gm4588, and Gm4607 . This finding indicates that RPL28 influences rRNA modifications beyond its structural role in the ribosome.

The significance of these methylation changes lies in their potential to alter ribosome function and translation dynamics. rRNA methylation is known to affect ribosome assembly, stability, and translational fidelity. The specific modification of Am2388, Gm4588, and Gm4607 sites following RPL28 depletion suggests that this protein participates in regulating specialized ribosomes with distinct functional properties.

For researchers investigating this emerging area, several methodological considerations are important:

• Advanced Methylation Analysis Techniques: Beyond RiboMethSeq, researchers should consider implementing complementary approaches such as bisulfite sequencing, methylation-specific PCR, or mass spectrometry to comprehensively characterize methylation changes.

• Integration with Translation Studies: Correlate methylation alterations with changes in translation efficiency, fidelity, and selectivity using ribosome profiling, polysome analysis, or reporter assays.

• Protein Interaction Networks: Investigate whether RPL28 directly interacts with known RNA methyltransferases or other epigenetic regulators using co-immunoprecipitation or proximity labeling approaches.

• Structural Biology Approaches: Implement cryo-EM or crystallography studies to determine how RPL28 positioning within the ribosome might influence methylation of specific rRNA sites.

This connection between RPL28 and rRNA methylation represents an exciting frontier in understanding how ribosomal proteins contribute to translation regulation through epigenetic mechanisms. The specific methylation sites affected by RPL28 depletion may serve as important markers for specialized ribosome populations that mediate selective translation in different cellular contexts or disease states.

How can RPL28 antibodies be utilized in studies of specialized ribosomes and selective translation?

The concept of specialized ribosomes—functionally distinct ribosome subpopulations that preferentially translate specific mRNAs—has emerged as an important area of research. RPL28 antibodies offer valuable tools for investigating this phenomenon, particularly given the protein's influence on rRNA methylation and MHC class I peptide generation . Researchers can implement several innovative approaches using RPL28 antibodies to study specialized ribosomes:

• Ribosome Immunoprecipitation (RIP): Using RPL28 antibodies to isolate intact ribosomes followed by RNA sequencing of associated mRNAs can reveal whether RPL28-containing ribosomes preferentially translate specific transcripts. This approach can be enhanced through crosslinking to capture transient ribosome-mRNA interactions.

• Proximity-Based Labeling: Combining RPL28 antibodies with proximity labeling techniques (BioID, APEX) can identify proteins that selectively associate with RPL28-containing ribosomes under different cellular conditions or stress states.

• Single-Molecule Imaging: Implementing super-resolution microscopy with fluorescently-labeled RPL28 antibodies enables visualization of ribosome heterogeneity and distribution within cells, potentially revealing specialized translation compartments.

• Translational Efficiency Analysis: Following RPL28 manipulation (knockdown/overexpression), researchers can use antibodies to monitor changes in global versus selective translation through polysome profiling combined with RNA sequencing or proteomics.

• rRNA Modification Mapping: RPL28 antibodies can facilitate the isolation of specific ribosome populations for subsequent analysis of rRNA modification patterns, building on findings that RPL28 depletion alters methylation at specific 28S rRNA sites (Am2388, Gm4588, and Gm4607) .

• Stress Response Studies: Examining how cellular stressors affect RPL28 incorporation into ribosomes can reveal mechanisms of translational reprogramming during stress adaptation.

When implementing these approaches, researchers should consider using multiple antibodies targeting different RPL28 epitopes to ensure robust findings, and include appropriate controls such as IgG or knockdown samples. These methods collectively offer powerful tools for understanding how RPL28 contributes to ribosome heterogeneity and selective translation, with potential implications for development, disease, and therapeutic interventions targeting translation.

What are the latest methodological advances in studying RPL28 interactions with the immunosurveillance system?

Recent discoveries highlighting RPL28's role in regulating MHC class I peptide generation have opened new avenues for investigating the intersection between ribosomal function and immunosurveillance . Researchers exploring this emerging field can leverage several cutting-edge methodological approaches:

• Integrated Peptidome and Immunopeptidome Analysis: Combining mass spectrometry-based identification of MHC-bound peptides with RPL28 manipulation (knockdown/overexpression) allows comprehensive mapping of how this ribosomal protein influences the repertoire of presented antigens. This approach has revealed that RPL28 depletion enhances both ubiquitin-dependent and ubiquitin-independent peptide presentation .

• Live-Cell Immunosurveillance Imaging: Advanced microscopy techniques employing fluorescently-labeled RPL28 antibodies alongside MHC class I tracking can visualize the temporal and spatial relationship between RPL28-containing ribosomes and antigen presentation machinery.

• Rapidly Degraded Polypeptide (DRiP) Monitoring: Since RPL28 influences the generation of DRiPs that contribute significantly to the immunopeptidome, researchers can implement pulse-chase experiments with RPL28 antibody-based isolation to characterize how this protein regulates DRiP synthesis and processing.

• T-Cell Recognition Assays: Functional assessment of how RPL28 manipulation affects T-cell recognition can be conducted using co-culture systems with RPL28-depleted target cells and antigen-specific T-cells, measuring activation markers, cytokine release, and cytotoxicity.

• Dual-Omics Approach: Integrating ribosome profiling (to identify translation changes) with immunopeptidome analysis following RPL28 modulation can establish direct links between translational events and antigen presentation.

• Conditional Knockout Models: Tissue-specific or inducible RPL28 knockout models combined with immunological challenges offer in vivo systems to examine how RPL28 influences immune surveillance in physiologically relevant contexts.